A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy

Zhou Z., Feng Z., Hu D., Yang P., Gur M., Bahar I., ...More

EBIOMEDICINE, vol.44, pp.98-111, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 44
  • Publication Date: 2019
  • Doi Number: 10.1016/j.ebiom.2019.05.011
  • Journal Name: EBIOMEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.98-111
  • Istanbul Technical University Affiliated: Yes


Background: Triple negative breast cancers (TNBCs) have a poor prognosis and are not amenable to endocrine- or HER2-targeted therapies. The malignant and invasive feature of TNBCs is correlated with its high cancer stem cell population. Recent results from us and others have unveiled an oncogenic role for the PRMT5-KLF4 axis in regulating tumor progression by orchestrating the sternness in mammary tumor cell as well as genome stability. Methylation of KLF4 by PRMT5 leads to KLF4 stabilization, resulting in promoting mitogenesis.